⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351366 | 0.72 | HMGCR (0.30) | — | |
| SCHEMBL16875688 | 0.72 | CA12 (0.33) | — | |
| SCHEMBL7209074 | 0.72 | POLB (0.35) | — | |
| SCHEMBL230240 | 0.72 | CA12 (0.33) | — | |
| SCHEMBL913291 | 0.70 | POLB (0.34) | — | |
| SCHEMBL8629345 | 0.68 | — | — | |
| SCHEMBL3132415 | 0.67 | CA12 (0.34) | — | |
| SCHEMBL9533869 | 0.67 | GLA (0.35) | — | |
| SCHEMBL7571252 | 0.67 | MT-CO2 (0.30) | — | |
| SCHEMBL8530390 | 0.66 | SMN1; SMN2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059906-B2 | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-13 | — | — | US | disclosed |
| CN-105358175-B | anti-CCL 2 and anti-LOXL 2 combination therapy for the treatment of scleroderma | 夏尔人类遗传性治疗公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-2999484-B1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | SHIRE HUMAN GENETIC THERAPIES (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2150282-B1 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | REGENTIS BIOMATERIALS LTD (IL) | 2018-04-11 | — | — | EP | disclosed |
| US-20170182214-A1 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | REGENTIS BIOMATERIALS LTD. (IL) | 2017-06-29 | — | — | US | disclosed |
| US-9624259-B2 | Compositions and methods for scaffold formation | REGENTIS BIOMATERIALS LTD. (IL) | 2017-04-18 | — | — | US | disclosed |
| EP-2497505-B1 | Compositions and methods for scaffold formation | REGENTIS BIOMATERIALS LTD (IL) | 2016-08-10 | — | — | EP | disclosed |
| EP-2999484-A1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | Shire Human Genetic Therapies, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20160083482-A1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| WO-2014190316-A1 | ANTI-CCL2 AND ANTI-LOXL2 COMBINATION THERAPY FOR TREATMENT OF SCLERODERMA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20010044147-A1 | Synthetic biodegradable amphipathic lipids, may include targeting agents | CELL GENESYS, INC. | 2001-11-22 | — | — | US | disclosed |
| US-6290952-B1 | Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2001-09-18 | — | — | US | disclosed |
| US-6193967-B1 | ADMINISTERING BISPECIFIC MOLECULE, COMPRISING: BINDING SPECIFICITY FOR HUMAN HIGH DENSITY LIPOPROTEIN (HDL), OR FRAGMENT AND FOR AN FC.GAMMA. RECEPTOR FOR IMMUNOGLOBULIN G FOR TREATING AND PROPHYLAXIS OF ATHEROSCLEROSIS | MORGANELLI PETER M (US) | 2001-02-27 | — | — | US | disclosed |
| US-5897861-A | Bispecific reagents for AIDS therapy | MEDAREX, INC. (US) | 1999-04-27 | — | — | US | disclosed |
| US-5762930-A | Bispecific reagents for redirected targeting of human lipoproteins | TRUSTEES OF DARTMOUTH COLLEGE, THE | 1998-06-09 | — | — | US | disclosed |
| EP-0833613-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996037194-A1 | DELIVERY VEHICLES COMPRISING STABLE LIPID/NUCLEIC ACID COMPLEXES | SOMATIX THERAPY CORPORATION (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0721501-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHOSPHATASE OR A DERIVATIVE THEREOF | RIJKSUNIVERSITEIT TE GRONINGEN (NL) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995005456-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHOSPHATASE OR A DERIVATIVE THEREOF | RIJKSUNIVERSITEIT TE GRONINGEN (NL) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994008038-A1 | BISPECIFIC REAGENTS FOR REDIRECTED TARGETING OF LOW DENSITY LIPOPROTEIN | TRUSTEES OF DARTMOUTH COLLEGE (US) | 1994-04-14 | — | — | WO | disclosed |